TZ Ref No.: TZ-26-1417358
RIoBORG - Radiation-Induced Resistance in Triple-Negative Breast Cancer Organoids: Decoding the Role of Dose Fractionation and the Tumour Microenvironment in Precision Radiotherapy
Doc ref no.
1012•••
Sector
Healthcare and Medicine
Contract Date
27 Mar 2026
Contract Value
EUR ••••••
Contract Intelligence
AI opportunity notes and scope analysis for this contract award
Opportunity Notes
A structured breakdown of scope, eligibility requirements, submission steps, and key conditions — extracted directly from the official notice.
Sign in to unlock Bid Fit & AI Opportunity Intelligence
TenderZenith calculates a personalized qualification score against your company profile and extracts structured intelligence from tender documents with your 7-Day Pro Trial (No Credit Card Required).
Official Award Result
Status: Contract Awarded
Award Date: 27 Mar 2026
Awarded Contractor / Winner
CENT•••
Awarded Contract Value:
EUR 226,420.56
Execution Period:
01 Sep 2026 → 31 Aug 2028
(730 days)
Contract Description
Radiotherapy fails in up to 40% of triple-negative breast cancer (TNBC) patients due to radioresistance mechanisms that remain poorly understood. RIoBORG (Radiation-Induced Resistance in Breast Cancer Organoids) addresses this urgent challenge using patient-derived xenograft...